{"url_path":"/sec/grtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001563577-26-000014-index.html","accession_number":"0001563577-26-000014","cik":"0001563577","ticker":"GRTX","issuer_name":"Galera Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1563577/0001563577-26-000014-index.html","primary_entity_key":"0001563577","primary_entity_name":"Galera Therapeutics, Inc."},"word_count":333,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nThe exhibits listed on the Exhibit Index are either filed or furnished with this report or incorporated herein by reference.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\nForm\n\n \n\nExhibit\n\n \n\nFiling\n\nDate\n\n  10.1*#\n\n \n\n[Letter Agreement, dated as of February 6, 2026, by and between the Company and Joel Sussman.](grtx-ex10_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n  10.2*\n\n \n\n[Third Amendment to Asset Purchase and Sale Agreement, dated as of February 26, 2026, by and between the Company and Biossil Inc.](grtx-ex10_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n  31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](grtx-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n  31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](grtx-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n  32.1**\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](grtx-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n  32.2**\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](grtx-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n# Indicates management contract or compensatory plan.\n\n† Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).\n\n \n\n \n\n \n\n \n\n28\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nGalera Therapeutics, Inc.\n\nDate: May 14, 2026\n\nBy:\n\n/s/ J. Mel Sorensen, M.D.\n\nJ. Mel Sorensen, M.D.\n\nChief Executive Officer and President\n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Joel Sussman\n\nJoel Sussman\n\nChief Accounting Officer\n\n \n\n \n\n \n\n(principal financial officer and principal accounting officer)\n\n \n\n29"}